| INTRODUCTION
Crohn's disease is a chronic inflammatory bowel disease characterised by granulomatous inflammation, most commonly involving the terminal ileum and colon. The onset is most frequently in the second to fourth decade with characteristic symptoms of abdominal pain, diarrhoea, and weight loss and potential systemic and extraintestinal complications. Most patients have alternating periods of relapse and remission with half of patients requiring surgery within 10 years of diagnosis. The approach to treatment has evolved from control of symptoms to preventing progression of the disease.
Therefore, treatments that safely maintain long-term remission are essential. 1 Treatment guidelines for Crohn's disease recommend maintenance therapy after remission is achieved, particularly for moderateto-high risk patients. 2 Potential benefits include reduction in hospitalisation and surgery and improved quality of life. 3, 4 Long-term efficacy has been demonstrated with azathioprine/mercaptopurine, 5 methotrexate, 6 tumour necrosis factor (TNF) antagonists, [7] [8] [9] [10] [11] natalizumab, 12 and vedolizumab. 13 Although TNF antagonists have significantly advanced the care of Crohn's disease, their efficacy is limited 14 and the development of anti-drug antibodies is associated with loss of response. [15] [16] [17] In addition, potential significant side effects of maintenance treatments include bone marrow suppression, 18 malignancy, 19, 20 and serious infections. 21, 22 Therefore, a need exists for safer agents that have demonstrated improved long-term maintenance efficacy.
Ustekinumab is a monoclonal antibody to the p40 subunit of interleukin-12 and interleukin-23 that has been approved for use in the treatment of psoriasis, psoriatic arthritis, and Crohn's disease. 23 Both clinical trial and registry data have confirmed the positive long-term efficacy and safety profile of ustekinumab in psoriasis. [24] [25] [26] The efficacy and safety of ustekinumab in Crohn's disease through 1 year has been previously established in the UNITI-1 and UNITI-2 (8 weeks) and IM-UNITI (44 weeks) studies in patients who have failed TNF antagonists or conventional therapies (predominantly regimens excluding anti-TNF medications). 27 Here, we report the IM-UNITI long-term extension data demonstrating the maintenance of response and remission (Week 92) with a positive safety profile (Week 96).
2 | ME TH ODS
| Study design and endpoints
IM-UNITI is a continuing Phase 3 ustekinumab maintenance study in patients with Crohn's disease. The Phase 3 programme included two 8-week, identically designed, induction studies (UNITI-1 and UNITI-2) with distinct populations and one maintenance study ( Figure 1 ).
The detailed study designs, eligibility criteria, and results for the UNITI and IM-UNITI studies through Week 44 have been previously published. 27 Briefly, UNITI-1 patients were required to have received one or more TNF antagonists at approved doses and to have met the criteria for primary nonresponse (the absence of a response), secondary nonresponse (a response that was not maintained), or to have had unacceptable side effects to TNF antagonists. Patients were evaluated for antibodies to ustekinumab every 6 months. Analyses of antibodies to ustekinumab were performed using a validated, drug-tolerant electro-chemiluminescence immunoassay, in which ustekinumab was used to capture and detect induced immune responses to ustekinumab. Janssen or its designee assayed these samples, under conditions in which the identification of the patient and treatment assignment was blinded.
| Statistical analysis
Because placebo patients discontinued the study after treatment assignments were unblinded to investigative sites (after the last patient completed Week 44 and database lock and subsequent analyses were completed), direct comparisons and/or statistical comparisons of efficacy results between placebo and ustekinumab treatment groups throughout the extension were not possible.
Demographic and baseline disease characteristics, efficacy and safety analyses were based on all patients treated with at least 1 administration of study agent during the long-term extension.
Descriptive statistics (eg, mean, median, standard deviation, interquartile range, minimum and maximum) were used to summarise continuous variables. Counts and percentages were used to summarise categorical variables.
For the IM-UNITI long-term extension, three types of analyses were conducted for remission data. Details of these analyses and the populations included are described in Table 1 . In brief, they include (1) Analysis of patients who entered the long-term extension, Table 3 ).
| Clinical remission by induction study, Weeks

44-92
The proportions of patients in clinical remission were generally maintained from Week 44 through Week 92 for patients from both the UNITI-1 and UNITI-2 populations ( Figure 2B ). 
| Clinical response
At Week 92, the proportions of patients in clinical response were similar for patients in the ustekinumab 90 mg every 12 weeks (83.3%) and every 8 weeks (80.5%) groups and lower in patients with prior dose-adjustment (67.6%) ( Table 3) . 
SF-36
The median SF-36 scores at Week 0 of IM-UNITI were similar across treatment groups (Table 4) . At Week 92, comparable results were observed among these groups in the proportion of patients with at least a five-point improvement in both the SF-36 physical and mental component scores ( 
| Weeks 44-96
Safety events (per hundred patient-years) were similar among all The proportions of patients with 1 or more injection-site reactions was 2.0% (n = 11) for ustekinumab patients and 0.6% (n = 6) for placebo patients with no reports of serious reactions, anaphylaxis or serum sickness-like reactions.
| Immunogenicity in randomised patients entering long-term extension
A total of 237 randomised patients who received ustekinumab during the long-term extension had appropriate samples for antibody to ustekinumab status through Week 96. Across all randomised treatment groups, 4.2% (10/237) of ustekinumab subcutaneous-treated patients were positive for antibodies to ustekinumab. Among patients on continuous 90 mg every 8 weeks treatment, the rate of antibodies to ustekinumab was 2.4%, similar to the rate seen in this group at 44 weeks. 27 Of note, rates of antibodies to ustekinumab were higher among patients who were randomised to placebo (8.2%; 5/61).
| DISCUSSION
IM-UNITI is the 5-year maintenance study in the Phase 3 pivotal programme for treatment of patients with Crohn's disease with ustekinumab. As previously shown, through 44 weeks of treatment, statistically significant evidence was generated demonstrating that treatment with subcutaneous ustekinumab 90 mg every 12 weeks or every 8 weeks was effective in maintaining clinical response and remission in patients with moderate-to-severe Crohn's disease. 27 Our findings confirm that in ustekinumab induction responders, Many controlled maintenance studies of biological agents have been limited to 1 year or less in duration, 7, 8, 11, 12 with the exceptions of adalimumab and vedolizumab. 9, 10, 13 Recognising the challenges of cross-study comparisons, due to differences in study populations, well as the nonrandomised and randomised groups), rates of response and remission were also slightly lower than the randomised every 8 weeks and every 12 weeks groups, but were similarly maintained. While some data have been published on predictors of response to ustekinumab in Crohn's disease patients, further analyses to identify patients who are most likely to achieve maximum benefit from ustekinumab would be helpful.
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Rates of patients who developed anti-drug antibodies were low and formation of antibodies did not impact response and remission rates. In randomised patients who received continuous treatment, the number of patients with anti-drug antibodies remained low and was consistent from Week 44 through Week 96. 27 Randomised patients who received an induction dose of ustekinumab followed by placebo had higher rates of antibodies, suggesting that drug exposure followed by a significant gap in treatment may increase the risk of antibody formation. However, even this proportion with antibodies (8%) is low compared to anti-drug antibody rates seen with other approved Crohn's disease biologics, 32 particularly when those drugs are assessed using similar high sensitivity, drug tolerant assays. identified. Additional efficacy and safety data from IM-UNITI will continue to be generated through 5 years of maintenance.
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